Helen M. Thackray - Net Worth and Insider Trading
Helen M. Thackray Net Worth
The estimated net worth of Helen M. Thackray is at least $1 Million dollars as of 2024-04-29. Helen M. Thackray is the Chief R&D Officer of BioCryst Pharmaceuticals Inc and owns about 207,275 shares of BioCryst Pharmaceuticals Inc (BCRX) stock worth over $885,064. Helen M. Thackray is also the SVP Clinical Development, CMO of GlycoMimetics Inc and owns about 148,615 shares of GlycoMimetics Inc (GLYC) stock worth over $230,353. Details can be seen in Helen M. Thackray's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Helen M. Thackray has not made any transactions after 2023-04-03 and currently still holds the listed stock(s).
Transaction Summary of Helen M. Thackray
Helen M. Thackray Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Helen M. Thackray owns 3 companies in total, including BioCryst Pharmaceuticals Inc (BCRX) , GlycoMimetics Inc (GLYC) , and Immunogen Inc (IMGN) .
Click here to see the complete history of Helen M. Thackray’s form 4 insider trades.
Insider Ownership Summary of Helen M. Thackray
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc | 2023-04-03 | director |
| GLYC | GlycoMimetics Inc | 2017-12-08 | VP Clinical Development & CMO |
| IMGN | Immunogen Inc | 2021-09-22 | director |
Helen M. Thackray Latest Holdings Summary
Helen M. Thackray currently owns a total of 2 stocks. Among these stocks, Helen M. Thackray owns 207,275 shares of BioCryst Pharmaceuticals Inc (BCRX) as of April 3, 2023, with a value of $885,064 and a weighting of 79.35%. Helen M. Thackray also owns 148,615 shares of GlycoMimetics Inc (GLYC) as of December 8, 2017, with a value of $230,353 and a weighting of 20.65%.
Latest Holdings of Helen M. Thackray
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc | 2023-04-03 | 207,275 | 4.27 | 885,064 |
| GLYC | GlycoMimetics Inc | 2017-12-08 | 148,615 | 1.55 | 230,353 |
Holding Weightings of Helen M. Thackray
Helen M. Thackray Form 4 Trading Tracker
According to the SEC Form 4 filings, Helen M. Thackray has made a total of 2 transactions in BioCryst Pharmaceuticals Inc (BCRX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in BioCryst Pharmaceuticals Inc is the sale of 7,000 shares on April 3, 2023, which brought Helen M. Thackray around $58,030.
According to the SEC Form 4 filings, Helen M. Thackray has made a total of 0 transactions in GlycoMimetics Inc (GLYC) over the past 5 years. The most-recent trade in GlycoMimetics Inc is the sale of 2,000 shares on December 8, 2017, which brought Helen M. Thackray around $30,020.
Insider Trading History of Helen M. Thackray
- 1
Helen M. Thackray Trading Performance
Helen M. Thackray Ownership Network
Ownership Network List of Helen M. Thackray
Ownership Network Relation of Helen M. Thackray
Helen M. Thackray Owned Company Details
What does BioCryst Pharmaceuticals Inc do?
Who are the key executives at BioCryst Pharmaceuticals Inc?
Helen M. Thackray is the director of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include director & CEO Jon P Stonehouse , Vice President and CCO Charles K Gayer , and Exec Director & Finance - PAO Michael L Jones .
BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary
Over the past 18 months, Helen M. Thackray made 2 insider transaction in BioCryst Pharmaceuticals Inc (BCRX) with a net sale of 10,125. Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net sale of 411,673 shares made by Jon P Stonehouse , a net sale of 9,045 shares made by Michael L Jones , and a net sale of 31,515 shares made by Yarlagadda S Babu .
In summary, during the past 3 months, insiders sold 0 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 495,199 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 495,199 shares.
BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
BioCryst Pharmaceuticals Inc Insider Transactions
Helen M. Thackray Mailing Address
Above is the net worth, insider trading, and ownership report for Helen M. Thackray. You might contact Helen M. Thackray via mailing address: C/o Glycomimetics, Inc., 401 Professional Drive, Suite 250, Gaithersburg Md 20879.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
